Rhythm Biosciences Secures Manufacturing Agreement With US-Based Manufacturer for Cancer Blood Test Product

MT Newswires Live

02/03

Rhythm Biosciences (ASX:RHY) has executed a multi-year commercial supply agreement with Quansys Biosciences, a US-based manufacturer, to produce ColoSTAT reagent kits, the company's blood test product for cancer, according to a Tuesday Australian bourse filing.

The company said that the agreement provides scalable manufacturing capacity to support the ColoSTAT Access Program and commercial rollout and includes provisions for minimum order volumes and a pricing framework to support anticipated operational requirements.

The company added that the supply partnership reduces manufacturing scale-up and quality system risk following two years of successful assay development collaboration.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2608479418"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608479418\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608479418?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 15:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608479418","market":"us","top_or_hot":-1,"title":"Rhythm Biosciences Secures Manufacturing Agreement With US-Based Manufacturer for Cancer Blood Test Product","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/RHYN.AU\">Rhythm Biosciences</a> (ASX:RHY) has executed a multi-year commercial supply agreement with Quansys Biosciences, a US-based manufacturer, to produce ColoSTAT reagent kits, the company's blood test product for cancer, according to a Tuesday Australian bourse filing.</p><p>The company said that the agreement provides scalable manufacturing capacity to support the ColoSTAT Access Program and commercial rollout and includes provisions for minimum order volumes and a pricing framework to support anticipated operational requirements.</p><p>The company added that the supply partnership reduces manufacturing scale-up and quality system risk following two years of successful assay development collaboration.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rhythm Biosciences Secures Manufacturing Agreement With US-Based Manufacturer for Cancer Blood Test Product</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRhythm Biosciences Secures Manufacturing Agreement With US-Based Manufacturer for Cancer Blood Test Product\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-02-03 15:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/RHYN.AU\">Rhythm Biosciences</a> (ASX:RHY) has executed a multi-year commercial supply agreement with Quansys Biosciences, a US-based manufacturer, to produce ColoSTAT reagent kits, the company's blood test product for cancer, according to a Tuesday Australian bourse filing.</p><p>The company said that the agreement provides scalable manufacturing capacity to support the ColoSTAT Access Program and commercial rollout and includes provisions for minimum order volumes and a pricing framework to support anticipated operational requirements.</p><p>The company added that the supply partnership reduces manufacturing scale-up and quality system risk following two years of successful assay development collaboration.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7124","symbol_name":"保健護理服務","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2608479418","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608479418","pubTimestamp":1770102389,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Rhythm Biosciences  has executed a multi-year commercial supply agreement with Quansys Biosciences, a US-based manufacturer, to produce ColoSTAT reagent kits, the company's blood test product for cancer, according to a Tuesday Australian bourse filing.The company said that the agreement provides scalable manufacturing capacity to support the ColoSTAT Access Program and commercial rollout and includes provisions for minimum order volumes and a pricing framework to support anticipated operational requirements.The company added that the supply partnership reduces manufacturing scale-up and quality system risk following two years of successful assay development collaboration.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7124":"保健护理服务","RHY.AU":"RHYTHM BIOSCIENCES LTD"},"translate_title":"Rhythm Biosciences与美国制造商签订癌症血液检测产品制造协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHY.AU":1},"content_text":"Rhythm Biosciences (ASX:RHY) has executed a multi-year commercial supply agreement with Quansys Biosciences, a US-based manufacturer, to produce ColoSTAT reagent kits, the company's blood test product for cancer, according to a Tuesday Australian bourse filing.The company said that the agreement provides scalable manufacturing capacity to support the ColoSTAT Access Program and commercial rollout and includes provisions for minimum order volumes and a pricing framework to support anticipated operational requirements.The company added that the supply partnership reduces manufacturing scale-up and quality system risk following two years of successful assay development collaboration.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}